uniQure N.V. (NASDAQ: QURE) is one of 306 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare uniQure N.V. to related companies based on the strength of its institutional ownership, analyst recommendations, valuation, risk, earnings, profitability and dividends.
Insider and Institutional Ownership
30.0% of uniQure N.V. shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 0.7% of uniQure N.V. shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
uniQure N.V. has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, uniQure N.V.’s peers have a beta of 5.89, meaning that their average stock price is 489% more volatile than the S&P 500.
This is a breakdown of recent recommendations for uniQure N.V. and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|uniQure N.V. Competitors||786||3128||11411||227||2.71|
uniQure N.V. currently has a consensus target price of $16.83, indicating a potential upside of 5.94%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.30%. Given uniQure N.V.’s peers higher probable upside, analysts plainly believe uniQure N.V. has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares uniQure N.V. and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|uniQure N.V.||$25.10 million||-$73.37 million||-6.09|
|uniQure N.V. Competitors||$290.00 million||$35.57 million||150.91|
uniQure N.V.’s peers have higher revenue and earnings than uniQure N.V.. uniQure N.V. is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares uniQure N.V. and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|uniQure N.V. Competitors||-5,315.62%||-487.39%||-42.71%|
uniQure N.V. peers beat uniQure N.V. on 7 of the 12 factors compared.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington’s disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.